sb 203580 has been researched along with formononetin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (formononetin) | Trials (formononetin) | Recent Studies (post-2010) (formononetin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 483 | 10 | 314 |
| Protein | Taxonomy | sb 203580 (IC50) | formononetin (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 3.6225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazer, FW; Lim, W; Park, S; Song, G | 1 |
1 other study(ies) available for sb 203580 and formononetin
| Article | Year |
|---|---|
The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
Topics: Analysis of Variance; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Inhibitors; Female; G1 Phase; Humans; Imidazoles; Isoflavones; MAP Kinase Signaling System; Matrix Metalloproteinases; Membrane Potential, Mitochondrial; Morpholines; Nitriles; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Reactive Oxygen Species; Resting Phase, Cell Cycle; Signal Transduction | 2018 |